Atreca | Biotech Strategy Blog

A look at early stage trials debuting at ASCO23

Chicago River Bridge

Early stage clinical trials can often turn out to be a bridge to future success or an unexpected dunk in the water, depending on how the outcomes go.

The path to success in Developmental Therapeutics is often paved with many unexpected trials and tribulations.

The important factor though is not whether or not companies experience them – because they will – but how well they handle the issues which present along the way.

In our latest report from ASCO23 we take a look at three phase 1 trials and one phase 2 study to explore the opportunities and challenges involved for four very different companies…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

ASCO23 Preview 1 – W2W4 in Developmental Therapeutics

Springing between meetings

This time of year always brings a flurry of data across different conferences as we start winding up our AACR coverage, spring forward to the ASCO abstract title drop and prepare for the forthcoming ASGCT meeting.

Of course, much like the weather of late there are always uncertainties involved when looking at abstract titles.

We may know, for example, that certain trials have been announced as positive having met their pre-defined criteria, but as to the exact magnitude of the effect and how much benefit is actually offered in terms of outcomes is another story entirely!

It would be impossible to review all of the meeting in one go, hence we’ll be offering a series of snapshots and discussion highlighting different key topics over the next few weeks.

Here are our notes on the first one in the series…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

When everyone zigs, zag

In our current mini-series exploring emerging biotech companies with early pipelines and novel targets, we investigate some interesting approaches that are not common place. As large cap Pharmaland companies seem overly focused on hunting for the next checkpoint target, smaller biotechs are more nimbly coming up with some fresh ideas that might have solid merit down the road.

All aboard!

This is one of those such innovative companies.

What if there was a different approach where we can learn from the immune system’s response to a cancer? Sounds obvious and intuitive when put so baldly, yet few companies are actually doing that in practice.

What would such a process and pipeline look like?

Come and find out for yourselves – you may well be surprised because some ideas that seem crazy at first blush, could turn out to be rather useful indeed…

To learn more from our oncology coverage and get a heads up on insights emerging our latest analysis and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘Atreca’

A look at early stage trials debuting at ASCO23

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

ASCO23 Preview 1 – W2W4 in Developmental Therapeutics

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

When everyone zigs, zag

To learn more from our oncology coverage and get a heads up on insights emerging our latest analysis and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.